Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Buy
56
AUPH Quote, Financials, Valuation and Earnings
Last price:
$8.94
Seasonality move
:
22.59%
Day range:
$8.92 - $9.23
52-week range:
$4.71 - $10.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.92x
P/B ratio:
3.33x
Volume:
1.6M
Avg. volume:
1.6M
1-year change:
1.35%
Market cap:
$1.3B
Revenue:
$175.5M
EPS (TTM):
-$0.14
Analysts' Opinion
-
Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Aurinia Pharmaceuticals has an estimated upside of 20% from its current price of $9.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $9.03.
Fair Value
-
According to the consensus of 0 analysts, Aurinia Pharmaceuticals has 20% upside to fair value with a price target of -- per share.
AUPH vs. S&P 500
-
Over the past 5 trading days, Aurinia Pharmaceuticals has underperformed the S&P 500 by -1.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aurinia Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aurinia Pharmaceuticals has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Aurinia Pharmaceuticals reported revenues of $67.8M.
Earnings Growth
-
Aurinia Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aurinia Pharmaceuticals reported earnings per share of $0.10.
Enterprise value:
944.2M
EV / Invested capital:
2.43x
Price / LTM sales:
5.92x
EV / EBIT:
--
EV / Revenue:
4.28x
PEG ratio (5yr expected):
--
EV / Free cash flow:
33.36x
Price / Operating cash flow:
46.06x
Enterprise value / EBITDA:
215.07x
Gross Profit (TTM):
$192.3M
Return On Assets:
-4.19%
Net Income Margin (TTM):
-10.23%
Return On Equity:
-5.99%
Return On Invested Capital:
-5.99%
Operating Margin:
17.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $129M | $158.9M | $220.4M | $54.5M | $67.8M | |
| Gross Profit | $124.2M | $148.7M | $192.3M | $47.7M | $61.7M | |
| Operating Income | -$116.1M | -$90.1M | -$24.9M | -$16.3M | $11.7M | |
| EBITDA | -$110.4M | -$62M | $4.4M | -$6.5M | $20.9M | |
| Diluted EPS | -$0.83 | -$0.53 | -$0.14 | -$0.09 | $0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $411.6M | $329.2M | $459.7M | $426.5M | $440.5M | |
| Total Assets | $461.8M | $360.1M | $488.3M | $555M | $549.4M | |
| Current Liabilities | $23.9M | $37.5M | $41.8M | $73.9M | $78.6M | |
| Total Liabilities | $62.9M | $61.9M | $64.9M | $163.1M | $161.4M | |
| Total Equity | $398.8M | $298.2M | $423.4M | $391.9M | $388M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$115.9M | -$37.3M | $28.6M | -$13.3M | $17M | |
| Cash From Investing | -$63.1M | -$3.5M | -$6.2M | -$19.7M | -$10.6M | |
| Cash From Financing | $207.5M | $1.1M | -$31.6M | -$2.3M | -$2.7M | |
| Free Cash Flow | -$116.4M | -$38.1M | $28.3M | -$13.2M | $16.9M | |
AUPH
Sector
Market Cap
$1.3B
$43.9M
Price % of 52-Week High
84.63%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
1.76%
-0.74%
1-Year Price Total Return
1.35%
-29.11%
Beta (5-Year)
1.408
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.44
200-day SMA
Buy
Level
$6.37
Bollinger Bands (100)
Buy
Level
6.26 - 8.56
Chaikin Money Flow
Sell
Level
-181.5M
20-day SMA
Sell
Level
$9.18
Relative Strength Index (RSI14)
Buy
Level
51.75
ADX Line
Buy
Level
42.34
Williams %R
Buy
Level
-83.6735
50-day SMA
Buy
Level
$8.24
MACD (12, 26)
Buy
Level
0.30
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
374.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7853)
Buy
CA Score
(Annual)
Level (0.243)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (0.1537)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Stock Forecast FAQ
In the current month, AUPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AUPH average analyst price target in the past 3 months is --.
-
Where Will Aurinia Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aurinia Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Aurinia Pharmaceuticals?
Analysts are divided on their view about Aurinia Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aurinia Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Aurinia Pharmaceuticals's Price Target?
The price target for Aurinia Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AUPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aurinia Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AUPH?
You can purchase shares of Aurinia Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aurinia Pharmaceuticals shares.
-
What Is The Aurinia Pharmaceuticals Share Price Today?
Aurinia Pharmaceuticals was last trading at $8.94 per share. This represents the most recent stock quote for Aurinia Pharmaceuticals. Yesterday, Aurinia Pharmaceuticals closed at $9.03 per share.
-
How To Buy Aurinia Pharmaceuticals Stock Online?
In order to purchase Aurinia Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
